Merged with Disc Medicine in Mar 2023
GMTX - Gemini Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
GMTX price evolution
GMTX
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $104.66 | $113.13 | $124.07 | $140.1 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $106.03 | $113.33 | $124.28 | $140.44 |
| Current liabilities | ||||
| Accounts payable | $1.14 | $1.62 | $5.11 | $2.95 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $1.46 | $6.44 | $12.67 | $14.83 |
| Long term debt | $0.4 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1.46 | $6.44 | $12.67 | $15.6 |
| Shareholders' equity | ||||
| Retained earnings | -$210.29 | -$207.01 | -$199.92 | -$184.69 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.21 | |||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $140.1 | $1.34 | ||
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $120.75 | |||
| Total investments | ||||
| Total assets | $140.44 | $122.09 | ||
| Current liabilities | ||||
| Accounts payable | $2.95 | $0.1 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $14.83 | $0.6 | ||
| Long term debt | $0.4 | |||
| Total noncurrent liabilities | $116.5 | |||
| Total debt | ||||
| Total liabilities | $15.6 | $117.09 | ||
| Shareholders' equity | ||||
| Retained earnings | -$184.69 | -$0.81 | ||
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.74 | $7.23 | $13.48 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.46 | $0.1 | -$0.06 | |
| Net income | ||||
| Net income | -$3.28 | -$7.09 | -$15.23 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $0.82 | |||
| Operating income | -$0.82 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$0.81 | |||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.34 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$5.37 | -$2.46 | -$1.23 | $191.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$35.21 | -$28.29 | -$17.56 | $132.12 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | |
|---|---|---|---|---|
| Net income | -$0.81 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.42 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.34 | -$120.75 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $191.48 | $122.38 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $132.12 | $1.21 | ||
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 43.30M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 71.49 |
| Quick ratio | N/A |